Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01250171 · ClinicalTrials.gov registry record · Phase 2
The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT01250171 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 72 participants.
The verdict
NCT01250171, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
This study assessed the effects of a single intravenous dose of secukinumab (AIN457) 10 mg/kg or canakinumab (ACZ885) 10 mg/kg on the signs and symptoms of dry eye. In addition, the pharmacokinetic, pharmacodynamic, and safety profiles of secukinumab and canakinumab were assessed. Blood samples were collected for the analysis of the effect of secukinumab and canakinumab on select biomarkers.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Secukinumab 10 mg/kg
- BIOLOGICAL Canakinumab 10 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01250171
The ClinicalTrials.gov registry entry for NCT01250171 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01250171 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01250171 about?
NCT01250171 is a clinical study titled "The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients". This study assessed the effects of a single intravenous dose of secukinumab (AIN457) 10 mg/kg or canakinumab (ACZ885) 10 mg/kg on the signs and symptoms of dry eye. In addition, the pharmacokinetic, pharmacodynamic, and safety profiles of secukinumab and canakinumab were assessed. Blood samples were...
What is the current status of trial NCT01250171?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2010-11. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01250171?
The interventions under investigation include: Placebo (BIOLOGICAL), Secukinumab 10 mg/kg (BIOLOGICAL), Canakinumab 10 mg/kg (BIOLOGICAL).
Who is sponsoring clinical trial NCT01250171?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.